VEGF-A and PD-L1 Immunoexpression Association with Meningioma Histopathology Grade

Yunnica Yunnica, Afiati Afiati, Hermin Aminah Usman, Bethy Surjawathy Hernowo

Abstract


Histopathology grade of meningioma is one of the most common factors determining the prognosis and affects the risk of recurrence and aggressiveness of the tumor. Biological factors related to histopathological grade are vascular endothelial growth factor A (VEGF-A) and programmed death-ligand 1 (PD-L1). This research aimed to understand the association between VEGF-A and PD-L1 with meningioma histopathology grade. This is in vivo research on 60 paraffin blocks of meningioma cases at Dr. Hasan Sadikin General Hospital Bandung from April to November 2018. Paraffin block samples consist of grade I (30), grade II (15), and grade III (15) meningioma. Immunohistochemical staining of VEGF-A and PD-L1 performed to all samples. Data analyzed using the chi-square test with SPSS version 24.0 for Windows. The result shows a significant association between VEGF-A and PD-L1 immunoexpression with meningioma histopathology grade. PD-L1 is the most potent factor that influenced the histopathology grade of meningioma. The study concluded that the histopathology grade of meningiomas influenced by angiogenesis and immune checkpoints. VEGF-A and PD-L1 immunoexpression in meningioma considered as a factor that influences the aggressiveness of meningioma.

 

HUBUNGAN IMUNOEKSPRESI VEGF-A DAN PD-L1 DENGAN DERAJAT HISTOPATOLOGI MENINGIOMA

Derajat histopatologi meningioma merupakan salah satu faktor yang paling umum menentukan prognosis serta memengaruhi risiko rekurensi dan agresivitas tumor. Faktor biologi yang berhubungan dengan derajat histopatologi adalah vascular endothelial growth factor A (VEGF-A) dan programmed death-ligand 1 (PD-L1). Penelitian ini bertujuan mengetahui hubungan imunoekspresi VEGF-A dan PD-L1 dengan derajat histopatologi meningioma. Penelitian in vivo dilakukan pada 60 blok parafin kasus meningioma di Departemen Patologi Anatomi RSUP Dr. Hasan Sadikin Bandung dari April hingga November 2018. Sampel blok parafin terdiri atas meningioma derajat I (30), derajat II (15), dan derajat III (15). Pulasan imunohistokimia VEGF-A dan PD-L1 dilakukan terhadap semua sampel. Data dianalisis menggunakan uji chi-square dengam SPSS versi 24.0 untuk Windows. Hasil penelitian menunjukkan bahwa terdapat hubungan yang signifikan antara VEGF-A dan PD-L1 dengan derajat histopatologi meningioma. PD-L1 merupakan faktor paling kuat yang memengaruhi derajat histopatologi meningioma. Simpulan penelitian ini adalah derajat histopatologi meningioma dipengaruhi oleh faktor angiogenesis dan immune check point. Imunoekspresi VEGF-A dan PD-L1 pada meningioma dapat dipertimbangkan sebagai faktor yang memengaruhi agresivitas meningioma.


Keywords


Derajat histopatologi; histopathology grade; meningioma; PD-L1; VEGF-A

Full Text:

PDF

References


Perry A, Louis DN, Budka H, von Deimling A, Sahm F, Rushing EJ, et al. Meningioma. In: Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, editors. WHO classification of tumours of the central nervous system. 4th Revised Edition. Geneva: WHO Press; 2016. p. 232–45.

Osborn AG. Tumors of the meninges. In: Osborn AG, Hedlund GL, Salzman KL. Osborn’s brain: imaging, pathology and anatomy. 2nd Edition. Salt Lake City: Elsevier Inc.; 2018. p. 659–94.

Dho YS, Jung KW, Ha J, Seo Y, Park CK, Won YJ, et al. An updated nationwide epidemiology of primary brain tumors in Republic of Korea, 2013. Brain Tumor Res Treat. 2017;5(1):16–23.

Perry A. Tumours of the meninges. In: Love S, Perry A, Ironside J, Budka H, editors. Greenfield’s neuropathology. 9th Edition. Boca Raton: CRC Press; 2015. p. 1803–27.

Schniederjan MJ. Biopsy interpretation of the central nervous system. 2nd Edition. Philadelphia: Wolters Kluwer; 2018.

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359–86.

Johnson MD. PD-L1 expression in meningiomas. J Clin Neurosci. 2018;57:149–51.

Du Z, Abedalthagfi M, Aizer AA, McHenry AR, Sun HH, Bray MA, et al. Increased expression of the immune modulatory molecule PD-L1 (CD274) in anaplastic meningioma. Oncotarget. 2015;6(7):4704–16.

Jeung JA. Malignant (anaplastic) meningiomas. In: Yachnis A, Rivera-Zengotita M, editors. Neuropathology: a volume in the high-yield pathology series. 1st Edition. Philadelphia: Saunders; 2014. p. 144–5.

Velnar T. Meningiomas: pathology and clinical characteristics. In: Figueroa D, editor. Meningiomas: risk factors, treatment options and outcomes. New YorkNova Science Publishers, Inc.; 2016. p. 1–12.

Han MH, Kim CH. Risk factors of meningioma. In: Figueroa D, editor. Meningiomas: risk factors, treatment options and outcomes. New York: Nova Science Publishers, Inc.; 2016. p. 13–28.

Poon MTC, Leung GKK. Surgical treatment for intracranial meningioma in the elderly. In: Figueroa D, editor. Meningiomas: risk factors, treatment options and outcomes. New York: Nova Science Publishers, Inc.; 2016. p. 137–40.

Wu Y, Lucia K, Lange M, Kuhlen D, Stalla GK, Renner U. Hypoxia inducible factor-1 is involved in growth factor, glucocorticoid and hypoxia mediated regulation of vascular endothelial growth factor-A in human meningiomas. J Neurooncol. 2014;119(2):263–73.

Lee SH, Lee YS, Hong YG, Kang CS. Significance of COX-2 and VEGF expression in histopathologic grading and invasiveness of meningiomas. APMIS. 2014;122(1):16–24.

Huang MC, van Loveren HR. Anatomy and biology leptomeninges. In: DeMonte DF, McDermott MW, Al-Mefty O, editors. Al-Mefty’s meningiomas. 2nd Edition. New York: Thieme Medical Publishers, Inc.; 2011. p. 25–34.

Claus EB, Morrison AL. Epidemiology of meningiomas. In: DeMonte DF, McDermott MW, Al-Mefty O, editors. Al-Mefty’s meningiomas. 2nd Edition. New York: Thieme Medical Publishers, Inc.; 2011. p. 35–39.

Morrison AL, Rushing E. Pathology of meningiomas. In: DeMonte DF, McDermott MW, Al-Mefty O, editors. Al-Mefty’s meningiomas. 2nd Edition. New York: Thieme Medical Publishers, Inc.; 2011. p. 40–50.

Ragel BT, Jensen RL. Molecular biology of meningiomas: tumorigenesis and growth. In: DeMonte DF, McDermott MW, Al-Mefty O, editors. Al-Mefty’s meningiomas. 2nd Edition. New York: Thieme Medical Publishers, Inc.; 2011. p. 51–62.

Xue S, HU M, Li P, Ma J, Xie L, Teng F, et al. Relationship between expression of PD-L1 and tumor angiogenesis, proliferation, and invasion in glioma. Oncotarget. 2017;8(30):49702–12.

Alsaab HO, Sau S, Alzhrani R, Tatiparti K, Bhise K, Kashaw SK, et al. PD-1 and PD-L1 checkpoint signaling inhibition for cancer immunotherapy: mechanism, combinations, and clinical outcome. Front Pharmacol. 2017;8:561.

Momtaz P, Postow MA. Immunologic checkpoints in cancer therapy: focus on the programmed death-1 (PD-1) receptor pathway. Pharmgenomics Pers Med. 2014;7:357–65.

Lou E, Sumrall AL, Turner S, Peters KB, Desjardins A, Vredenburgh JJ, et al. Bevacizumab therapy for adults with recurrent/progressive meningioma: a retrospective series. J Neurooncol. 2012;109(1):63–70.

Nassehi D. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema. Dan Med J. 2013;60(4):B4626.

Franke AJ, Skelton WP IV, Woody LE, Bregy A, Shah AH, Vakharia K, et al. Role of bevacizumab for treatment-refractory meningiomas: a systematic analysis and literature review. Surg Neurol Int. 2018;9:133.

Gupta S, Bi WL, Dunn IF. Medical management of meningioma in the era of precision medicine. Neurosurg Focus. 2018;44(4):E3.

Barresi V. Angiogenesis in meningiomas. Brain Tumor Pathol. 2011;28(2):99–106.

Gelerstein E, Berger A, Jonas-Kimchi T, Strauss I, Kanner AA, Blumenthal DT, et al. Regression of intracranial meningioma following treatment with nivolumab: case report and review of the literature. J Clin Neurosci. 2017;37:51–3.

Imran H, Razia ET, Jawed HA, Nisar A, Choudry UK, Kumar A. Antibody targeted therapies in meningiomas: a critical review. J Surg Emerg Med. 2017;1(1):6.

Bi WL, Wu WW, Santagata S, Reardon DA, Dunn IF. Checkpoint inhibition in meningiomas. Immunotherapy. 2016;8(6):721–31.

Dharmalingam P, Roopesh Kumar VR, Verma SK. Vascular endothelial growth factor expression and angiogenesis in various grades and subtypes of meningioma. Indian J Pathol Microbiol. 2013;56(4):349–54.

Westendorf AM, Skibbe K, Adamczyk A, Buer J, Geffersb R, Hansen W, et al. Hypoxia enhances immunosuppression by inhibiting CD4+ effector T cell function and promoting Treg activity. Cell Physiol Biochem. 2017;41(4):1271–84.




DOI: https://doi.org/10.29313/gmhc.v7i3.4202

pISSN 2301-9123 | eISSN 2460-5441


Visitor since 19 October 2016: 


Free counters!


Global Medical and Health Communication is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.